Kura Oncology Set to Announce Q3 Financial Performance
Kura Oncology, Inc. (Nasdaq: KURA), a visionary biopharmaceutical company, is on the brink of announcing its financial results for the third quarter of 2024. The anticipation builds as the company is scheduled to release these earnings following the close of U.S. financial markets. This event is set for November 7, 2024, at 4:30 p.m. ET, showcasing the company’s commitment to transparency and communication with its investors.
Accessing the Live Conference Call
Investors and interested parties can participate in a live conference call by dialling (800) 225-9448 for domestic callers or (203) 518-9708 for those calling from outside the United States. Attendees will need to provide the conference ID: KURAQ3 to gain access to what promises to be an informative discussion regarding the company’s financial standing and strategic updates.
About Kura Oncology
Kura Oncology is dedicated to developing precision medicines that target cancerous cells. It is at the forefront of creating innovative treatments that are specifically designed to address the complexities of various cancer types. Kura’s drug portfolio features small molecule candidates aimed at inhibiting critical cancer signaling pathways, with a focus on delivering effective solutions to patients in need.
Pioneering Cancer Therapies
A standout candidate in Kura's pipeline is Ziftomenib, an oral medication that targets the menin-KMT2A protein-protein interaction. It has received Breakthrough Therapy Designation due to its potential in treating relapsed/refractory NPM1-mutant acute myeloid leukemia (AML). This significant progress reflects Kura's commitment to advancing treatment methodologies in oncology.
Ongoing Clinical Trials
Kura Oncology is currently advancing several clinical trials aimed at exploring the efficacy of Ziftomenib in combination therapies for newly diagnosed and relapsed/refractory cases of AML. This includes the KOMET-001 trial, which has completed patient enrollment, highlighting Kura’s proactive approach in the clinical space.
Exploring Innovative Inhibitors
In addition to Ziftomenib, Kura is evaluating KO-2806, a next-generation farnesyl transferase inhibitor, in a Phase 1 dose-escalation study. The aim is to assess its safety and efficacy both as a standalone treatment and in conjunction with existing therapies. This innovative approach offers hope for improved patient outcomes.
Combination Therapy Research
Among the promising candidates, Tipifarnib stands out as a potent farnesyl transferase inhibitor currently undergoing investigation in a Phase 1/2 trial. It is being tested in combination with alpelisib for patients suffering from PIK3CA-dependent head and neck squamous cell carcinoma. Kura's commitment to exploring combination therapies underscores its strategy to enhance treatment effectiveness.
Staying Informed on Developments
As a trailblazer in biopharmaceutical innovations, Kura Oncology encourages stakeholders to stay informed about its developments. The company's website serves as a valuable resource for the latest information regarding its therapeutic advancements and operational updates.
Company Contact Information
Kura Oncology prioritizes communication with both investors and the media. For inquiries, please contact:
Investors:
Pete De Spain
Executive Vice President, Investor Relations & Corporate Communications
(858) 500-8833
pete@kuraoncology.com
Media:
Cassidy McClain
Vice President
Inizio Evoke Comms
(619) 849-6009
cassidy.mcclain@inizioevoke.com
Frequently Asked Questions
When will Kura Oncology announce its Q3 financial results?
Kura Oncology will announce its third quarter financial results on November 7, 2024, after the close of U.S. markets.
How can I participate in the Kura Oncology conference call?
To join the live conference call, dial (800) 225-9448 for domestic calls or (203) 518-9708 for international calls and enter the conference ID: KURAQ3.
What is Ziftomenib used for?
Ziftomenib is an oral medication aimed at treating relapsed/refractory NPM1-mutant AML and has received Breakthrough Therapy Designation.
What ongoing trials is Kura Oncology conducting?
Kura is currently conducting clinical trials for Ziftomenib, KO-2806, and Tipifarnib to evaluate their effectiveness in various types of cancer.
How can I stay updated on Kura Oncology's developments?
You can visit Kura’s official website to keep up with the latest updates and information on their ongoing research and treatments.
